PT - JOURNAL ARTICLE AU - Zhang, Meng AU - Liu, Ergang AU - Cui, Yanna AU - Huang, Yongzhuo TI - Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer AID - 10.20892/j.issn.2095-3941.2017.0054 DP - 2017 Aug 01 TA - Cancer Biology and Medicine PG - 212--227 VI - 14 IP - 3 4099 - http://www.cancerbiomed.org/content/14/3/212.short 4100 - http://www.cancerbiomed.org/content/14/3/212.full SO - Cancer Biol Med2017 Aug 01; 14 AB - Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.